Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Introduction: Deficiency of adenosine deaminase 2 (DADA 2) syndrome is a monogenic auto-inflammatory vasculitic syndrome caused by loss of function mutations in the ADA2 gene. Disease manifestations are divided into three major phenotypes: inflammatory/vascular, immune dysregulation, and haematologic, with majority having significant overlap between these phenotypes. The disease has undergone extensive phenotypic expansion since its first description in 2014. It is autosomal recessively inherited and commonly presents with fever, recurrent strokes, livedo racemosa, and polyarteritis nodosa (PAN)-like features. Though the disease has its symptom onset early in childhood, various case series have described patients with symptom onset in adulthood. Visceral arterial aneurysms as a manifestation have been described in literature but not peripheral aneurysms. Here, we describe a young adult with DADA 2 syndrome presenting with peripheral arterial aneurysm involving the brachial artery.
Case Report: Patient had recurrent episodes of CVA since childhood, a history of orchitis, systemic hypertension, and new onset brachial artery aneurysm at the age of twenty-three. Diagnosis was confirmed by genetic analysis. Tumour necrosis factor inhibitors (TNFi) have emerged as the drug of choice for the treatment of DADA2 and studies revealed a drastic reduction in stroke risk after initiation of TNFi. Based on this experience, we have started the patient on adalimumab, and he is doing well for the past one year.
Conclusion: Peripheral artery aneurysm can be a manifestation of vasculitis in DADA 2 syndrome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183452 | PMC |
http://dx.doi.org/10.31138/mjr.120324.dai | DOI Listing |